- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06006754
Influence of Enteral Microbiome on Mortality of Patients With Cardiogenic Shock
Influence of Enteral Microbiome Composition and Microbiome Dependent Metabolites on Mortality of Patients With Cardiogenic Shock
Cardiogenic shock is associated with a high mortality. The microbiome is a double-edged sword which can convey protective and detrimental cardiovascular effects. The significance of the enteral micobiome on cardiovascular mortality of patients with cardiogenic shock is still not known.
This study aims to provide a deeper understanding of the role of the enteral microbiome and microbiome dependent metabolites in mortality and disease progression of patients with cardiogenic shock.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Christos Rammos, Prof. Dr.
- Phone Number: 4801 0049201723
- Email: christos.rammos@uk-essen.de
Study Contact Backup
- Name: Tienush Rassaf, Prof. Dr.
- Phone Number: 4801 0049201723
- Email: tienush.rassaf@uk-essen.de
Study Locations
-
-
NRW
-
Essen, NRW, Germany, 45147
- Recruiting
- University Hospital Essen
-
Contact:
- Christos Rammos, Professor
- Phone Number: 84808 +49 (0)201-723
- Email: christos.rammos@uk-essen.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- >18y
signs of cardiogenic shock regardless of etiology
- lactate >3mmol/L
- and signs of organ dysfunction (urine output <30 ml/h, cold extremities, altered mental status)
- and systolic blood pressure <90 mmHg for >30 minutes or need for vasopressor therapy
Exclusion Criteria:
- pregnancy/lactation period
- antibiotic treatment within >24h
- chronic inflammatory bowel disease
- short bowel syndrome
- artificial bowel outlet
- persistent diarrhea or vomiting in the past 3 months
- simultaneous participation in another interfering nutrition study
- active chemo or radiation therapy
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cardiogenic shock
|
No intervention: observational study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between enteral microbiome composition and mortality
Time Frame: Sampling will be performed within 24 hours of onset of cardiogenic shock and clinical evaluation will be performed after 1 month
|
Stool samples are collected and clinical evaluation will be performed at below mentioned time points
|
Sampling will be performed within 24 hours of onset of cardiogenic shock and clinical evaluation will be performed after 1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between TMAO serum level and mortality
Time Frame: Sampling will be performed within 24 hours of onset of cardiogenic shock and on day 3
|
Blood samples are collected at below mentioned time points
|
Sampling will be performed within 24 hours of onset of cardiogenic shock and on day 3
|
Correlation between SCFA serum level and mortality
Time Frame: Sampling will be performed within 24 hours of onset of cardiogenic shock and on day 3
|
Blood samples are collected at below mentioned time points
|
Sampling will be performed within 24 hours of onset of cardiogenic shock and on day 3
|
Correlation between inflammatory profile (CRP, PCT, Interleukin panel) and mortality
Time Frame: Sampling will be performed within 24 hours of onset of cardiogenic shock and on day 3
|
Blood samples are collected at below mentioned time points
|
Sampling will be performed within 24 hours of onset of cardiogenic shock and on day 3
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Christos Rammos, Prof. Dr., University Clinic Essen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Microbiome-Shock-Trial
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Microbial Colonization
-
Karolinska InstitutetCompletedMicrobial Colonization and Colorectal Disease
-
NHS FifeUniversity of TurkuUnknownDental Caries | Oral Microbial ColonizationUnited Kingdom
-
University Magna GraeciaRecruiting
-
BLIS Technologies LimitedRecruiting
-
Min-Tze LIONGInternational Islamic University MalaysiaRecruiting
-
VU University of AmsterdamWageningen University and Research; Maag Lever Darm Stichting; Cidrani; WholeFiber and other collaboratorsActive, not recruiting
-
BLIS Technologies LimitedActive, not recruiting
-
Becton, Dickinson and CompanyCompleted
-
Washington University School of MedicineCompletedMicrobial ColonizationUnited States
-
Cairo UniversityUnknown
Clinical Trials on Observational study
-
Taysha Gene Therapies, Inc.Withdrawn
-
University of Castilla-La ManchaRecruitingKnee OsteoarthritisSpain
-
AstraZenecaRecruiting
-
AstraZenecaRecruitingNon-Small Cell Lung CancerUnited States
-
University of ManitobaCompletedObesity | Pregnancy | Cesarean SectionCanada
-
Drexel UniversityCompletedOsteoporosisUnited States
-
Oslo University HospitalThe Research Council of NorwayRecruitingMesothelioma | Pseudomyxoma Peritonei | Colorectal Carcinoma | Ovarian CarcinomaNorway
-
Oslo University HospitalThe Research Council of NorwayActive, not recruiting
-
The Aurum Institute NPCKarolinska Institutet; Ludwig-Maximilians - University of Munich; University... and other collaboratorsUnknownRespiratory Tract Infections | Tuberculosis, PulmonaryMozambique, South Africa, Tanzania, Gambia
-
AstraZenecaParexelRecruitingSystemic Lupus ErythematosusItaly, Belgium, Germany, France, Canada, Austria, Sweden, Denmark, Israel, United Arab Emirates